CTIM-21. NRG-BN010: A SAFETY RUN-IN AND PHASE II STUDY EVALUATING THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA–TRIAL IN PROGRESS

Rupesh Kotecha; Ranjini Tolakanahalli; Minesh Mehta

CTIM-21. NRG-BN010: A SAFETY RUN-IN AND PHASE II STUDY EVALUATING THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA–TRIAL IN PROGRESS

Rupesh Kotecha
, Ranjini Tolakanahalli
, Minesh Mehta

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Neuro-oncology
Volume	24
State	Published - Jan 1 2022

Cite this

@article{95a8bd6b04564d2981709ac56b384540,

title = "CTIM-21. NRG-BN010: A SAFETY RUN-IN AND PHASE II STUDY EVALUATING THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA–TRIAL IN PROGRESS",

author = "Rupesh Kotecha and Ranjini Tolakanahalli and Minesh Mehta",

note = "Neuro-Oncology (2022) 24(Supplement\_7):vii64-vii64",

year = "2022",

month = jan,

day = "1",

language = "American English",

volume = "24",

journal = "Neuro-oncology",

}

TY - JOUR

T1 - CTIM-21. NRG-BN010: A SAFETY RUN-IN AND PHASE II STUDY EVALUATING THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA–TRIAL IN PROGRESS

AU - Kotecha, Rupesh

AU - Tolakanahalli, Ranjini

AU - Mehta, Minesh

N1 - Neuro-Oncology (2022) 24(Supplement_7):vii64-vii64

PY - 2022/1/1

Y1 - 2022/1/1

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/4803

M3 - Article

VL - 24

JO - Neuro-oncology

JF - Neuro-oncology

ER -

CTIM-21. NRG-BN010: A SAFETY RUN-IN AND PHASE II STUDY EVALUATING THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA–TRIAL IN PROGRESS

Other files and links

Cite this